where do we go from now, page-3

Hi Supertramp,

Your score of cce as 1 out of 8 on the biotech checklist. Let's keep it in context.

1. Successful products on the market - no. Not commercially successful & possibly not successful as a treatment, judging by sales. [They are proven products - no sales do not mean not successful. They have sales previously for the three products. We have no knowledge as to why the uptake of CCE's products has been slowed - Previously CEO,Troels, mentioned the surgeons were slowed at using the products. I think the products are expensive and also the procedures of efficacy may not be undertaken properly - they had this problem in Japan earlier. There are a whole range of issues but somehow there is no explanation being given by CCE the reason why uptake has been slowed]



2. A deep product pipeline with late-stage candidates - no. Three branded products, but all the same really (only ReCell available now). [Although the two, apart from ReCell, are the same There are still three products. They have to put aside ulcer because of cash burn]

3. Drugs and candidates that target large or underserved markets - yes, I guess

4. Partnerships and marketing agreements with blue-chip drug manufacturers - no [ They don't have it currently as they thought they could go it alone but realise that they need to tap into blue-chip partners/alliances to sell their products - at least they are looking at it now]

5. Research & development spending - no [No longer given that CCE is trying to conserve cash resources. It is a question about optimising resource allocation given that capital raising may not be forthcoming and that sale revenues may be slow. So, you would spend on areas that give you a better return than to burn cash and having no investment returns.]

6. Enough cash to fund operations for two years - no [unless they manage to pull in sale revenues at later stage. ]

7. Experienced management - no (the old management has proved to be very poor so far) - [They should have kept Troels]

8. Favorable financial analysis - no